Serina Therapeutics is a clinical-stage biotechnology company based in Huntsville, Alabama, US, developing next-generation therapies for neurological diseases using its proprietary POZ™ Platform. This cutting-edge drug delivery technology is designed to improve how medications are absorbed and tolerated, offering more consistent and effective treatment options.
Serina’s lead candidate, SER-252, is an investigational therapy for Parkinson’s Disease that aims to provide continuous dopaminergic stimulation (CDS) – a clinical strategy shown to reduce motor complications like dyskinesia in advanced PD patients.
Now, Serina is launching a clinical trial in Australia for individuals aged 40–80 with idiopathic Parkinson’s Disease who experience daily OFF episodes that are not optimally controlled with their current medications. Participants will stay at a Phase 1 unit for 7 days and return for a follow-up visit on Day 14. To support participation, Serina will cover travel costs for both patients and their caregivers, including hotel accommodations if needed.
This trial is part of Serina’s broader mission to bring science closer to patients and improve quality of life through precision drug delivery. If you or someone you know meets the criteria, this is a chance to contribute to groundbreaking research and help shape the future of Parkinson’s treatment.
Stay informed and contact us at the email address [email protected] for more information.
